Epigenomics AG
OTC: EPGNF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Jason Wouhra
- Employees
- 3
- Headquarters
- Heidelberg, Germany
- IPO year
- 2010
- Market cap
- $982.2K
- Website
- https://www.epigenomics.com
Loading EPGNF…
Loading profile data…Frequently asked questions about EPGNF
What does Epigenomics AG (EPGNF) do?
Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, Epi BiSKit,...
Where does EPGNF trade?
Epigenomics AG (EPGNF) trades on the Other OTC.
What sector is EPGNF in?
Epigenomics AG (EPGNF) operates in the Healthcare sector, specifically in the Medical - Specialties industry.
Who is the CEO of Epigenomics AG?
Jason Wouhra is the chief executive officer of Epigenomics AG (EPGNF).
Where is Epigenomics AG headquartered?
Epigenomics AG is headquartered in Germany.
Does EPGNF pay a dividend?
Epigenomics AG (EPGNF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EPGNF go public?
Epigenomics AG (EPGNF) completed its initial public offering in 2010.